LANOXIN PEDIATRIC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lanoxin Pediatric, and when can generic versions of Lanoxin Pediatric launch?
Lanoxin Pediatric is a drug marketed by Covis and is included in one NDA.
The generic ingredient in LANOXIN PEDIATRIC is digoxin. There are ten drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the digoxin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lanoxin Pediatric
A generic version of LANOXIN PEDIATRIC was approved as digoxin by RISING on December 23rd, 1999.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LANOXIN PEDIATRIC?
- What are the global sales for LANOXIN PEDIATRIC?
- What is Average Wholesale Price for LANOXIN PEDIATRIC?
Summary for LANOXIN PEDIATRIC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 87 |
| Clinical Trials: | 18 |
| DailyMed Link: | LANOXIN PEDIATRIC at DailyMed |
Recent Clinical Trials for LANOXIN PEDIATRIC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Turning Point Therapeutics, Inc. | Phase 1 |
| Yale University | Phase 2 |
| Jean Grem, MD | Phase 2 |
Pharmacology for LANOXIN PEDIATRIC
| Drug Class | Cardiac Glycoside |
US Patents and Regulatory Information for LANOXIN PEDIATRIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Covis | LANOXIN PEDIATRIC | digoxin | INJECTABLE;INJECTION | 009330-004 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
